• In early February 2026, Hims & Hers Health launched and then quickly halted access to a low-cost compounded semaglutide weight loss pill after intense regulatory scrutiny, an FDA crackdown on compounded GLP-1 drugs, and a patent infringement lawsuit from Novo Nordisk.
• This brief product rollout and reversal has spotlighted legal, regulatory, and safety questions around Hims & Hers’ broader GLP-1 offering and its model of marketing compounded medications at sharply lower prices than branded therapies.
• We’ll now examine how the abrupt retreat from compounded semaglutide, amid FDA and Novo Nordisk pressure, reshapes Hims & Hers’ investment narrative.

Find 52 companies with promising cash flow potential yet trading below their fair value.

What Is Hims & Hers Health's Investment Narrative?

To own Hims & Hers today, you have to believe its direct-to-consumer model, technology stack, and brand can keep scaling profitable telehealth across multiple categories, not just weight loss. The business is already generating over US$2.2 billion in revenue with positive earnings, but growth has moderated, profit margins have slipped, and the stock’s sharp 1-year pullback shows how fragile sentiment is. Near term, catalysts had centered on subscriber growth, cross-selling into new offerings like the Galleri multi-cancer test, and the benefit of buybacks. The abrupt compounded semaglutide launch and retreat now inserts legal and regulatory uncertainty directly into that story, particularly around GLP-1 products that had been seen as a key driver. Whether this episode proves a contained misstep or a structural constraint on one of Hims & Hers’ highest-profile categories is what investors are now debating.

However, one specific regulatory overhang could matter much more than the recent price drop. Despite retreating, Hims & Hers Health's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

The Simply Wall St Community’s 56 fair value estimates for Hims & Hers span roughly US$30 to over US$170, with some seeing very large upside. With the GLP-1 legal and regulatory overhang now front and center, you are looking at a business where growth drivers and headline risk may pull in opposite directions, which makes comparing these different viewpoints especially useful.

Explore 56 other fair value estimates on Hims & Hers Health - why the stock might be worth over 7x more than the current price!

Build Your Own Hims & Hers Health Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Hims & Hers Health research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Hims & Hers Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hims & Hers Health's overall financial health at a glance.

Searching For A Fresh Perspective?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Outshine the giants: these 27 early-stage AI stocks could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.